Stock Track | Veracyte Soars 7.81% Intraday Following Analyst Price Target Hike and Pipeline Updates

Stock Track02-26 23:12

Veracyte's stock soared 7.81% during intraday trading on Thursday, marking a significant upward movement for the diagnostics company.

The surge follows a bullish analyst update from Needham, where analyst Michael Matson maintained a Buy rating on the company and raised his price target to $48.00 from $44.00. The analyst cited accelerating growth, expanding margins, and pipeline-driven upside as key factors supporting the increased valuation.

Further positive sentiment is likely driven by the company's upcoming commercial and clinical activities. Veracyte plans to present numerous abstracts from its urology portfolio at a major medical symposium and is preparing to launch its TrueMRD test for muscle invasive bladder cancer, highlighting progress in its product pipeline.

Disclaimer: Investing carries risk. This is not financial advice. The above content should not be regarded as an offer, recommendation, or solicitation on acquiring or disposing of any financial products, any associated discussions, comments, or posts by author or other users should not be considered as such either. It is solely for general information purpose only, which does not consider your own investment objectives, financial situations or needs. TTM assumes no responsibility or warranty for the accuracy and completeness of the information, investors should do their own research and may seek professional advice before investing.

Comments

We need your insight to fill this gap

Leave a comment

{"i18n":{"language":"en_US"},"isChannel":false,"data":{"share":"https://ttm.financial/m/news/1120454129?lang=en_US&edition=fundamental","thumbnail":"","is_english":true,"pubTime":"2026-02-26 23:12","share_image_url":"https://static.laohu8.com/e9f99090a1c2ed51c021029395664489","id":"1120454129","market":"us","top_or_hot":-1,"title":"Stock Track | Veracyte Soars 7.81% Intraday Following Analyst Price Target Hike and Pipeline Updates","media":"Stock Track","content":"<p>Veracyte's stock soared 7.81% during intraday trading on Thursday, marking a significant upward movement for the diagnostics company.</p><p>The surge follows a bullish analyst update from Needham, where analyst Michael Matson maintained a Buy rating on the company and raised his price target to $48.00 from $44.00. The analyst cited accelerating growth, expanding margins, and pipeline-driven upside as key factors supporting the increased valuation.</p><p>Further positive sentiment is likely driven by the company's upcoming commercial and clinical activities. Veracyte plans to present numerous abstracts from its urology portfolio at a major medical symposium and is preparing to launch its TrueMRD test for muscle invasive bladder cancer, highlighting progress in its product pipeline.</p>","source":"ai_movement_en","html":"<!DOCTYPE html>\n<html>\n<head>\n<meta http-equiv=\"Content-Type\" content=\"text/html; charset=utf-8\" />\n<meta name=\"viewport\" content=\"width=device-width,initial-scale=1.0,minimum-scale=1.0,maximum-scale=1.0,user-scalable=no\"/>\n<meta name=\"format-detection\" content=\"telephone=no,email=no,address=no\" />\n<title>Stock Track | Veracyte Soars 7.81% Intraday Following Analyst Price Target Hike and Pipeline Updates</title>\n<style type=\"text/css\">\na,abbr,acronym,address,applet,article,aside,audio,b,big,blockquote,body,canvas,caption,center,cite,code,dd,del,details,dfn,div,dl,dt,\nem,embed,fieldset,figcaption,figure,footer,form,h1,h2,h3,h4,h5,h6,header,hgroup,html,i,iframe,img,ins,kbd,label,legend,li,mark,menu,nav,\nobject,ol,output,p,pre,q,ruby,s,samp,section,small,span,strike,strong,sub,summary,sup,table,tbody,td,tfoot,th,thead,time,tr,tt,u,ul,var,video{ font:inherit;margin:0;padding:0;vertical-align:baseline;border:0 }\nbody{ font-size:16px; line-height:1.5; color:#999; background:transparent; }\n.wrapper{ overflow:hidden;word-break:break-all;padding:10px; }\nh1,h2{ font-weight:normal; line-height:1.35; margin-bottom:.6em; }\nh3,h4,h5,h6{ line-height:1.35; margin-bottom:1em; }\nh1{ font-size:24px; }\nh2{ font-size:20px; }\nh3{ font-size:18px; }\nh4{ font-size:16px; }\nh5{ font-size:14px; }\nh6{ font-size:12px; }\np,ul,ol,blockquote,dl,table{ margin:1.2em 0; }\nul,ol{ margin-left:2em; }\nul{ list-style:disc; }\nol{ list-style:decimal; }\nli,li p{ margin:10px 0;}\nimg{ max-width:100%;display:block;margin:0 auto 1em; }\nblockquote{ color:#B5B2B1; border-left:3px solid #aaa; padding:1em; }\nstrong,b{font-weight:bold;}\nem,i{font-style:italic;}\ntable{ width:100%;border-collapse:collapse;border-spacing:1px;margin:1em 0;font-size:.9em; }\nth,td{ padding:5px;text-align:left;border:1px solid #aaa; }\nth{ font-weight:bold;background:#5d5d5d; }\n.symbol-link{font-weight:bold;}\n/* header{ border-bottom:1px solid #494756; } */\n.title{ margin:0 0 8px;line-height:1.3;color:#ddd; }\n.meta {color:#5e5c6d;font-size:13px;margin:0 0 .5em; }\na{text-decoration:none; color:#2a4b87;}\n.meta .head { display: inline-block; overflow: hidden}\n.head .h-thumb { width: 30px; height: 30px; margin: 0; padding: 0; border-radius: 50%; float: left;}\n.head .h-content { margin: 0; padding: 0 0 0 9px; float: left;}\n.head .h-name {font-size: 13px; color: #eee; margin: 0;}\n.head .h-time {font-size: 11px; color: #7E829C; margin: 0;line-height: 11px;}\n.small {font-size: 12.5px; display: inline-block; transform: scale(0.9); -webkit-transform: scale(0.9); transform-origin: left; -webkit-transform-origin: left;}\n.smaller {font-size: 12.5px; display: inline-block; transform: scale(0.8); -webkit-transform: scale(0.8); transform-origin: left; -webkit-transform-origin: left;}\n.bt-text {font-size: 12px;margin: 1.5em 0 0 0}\n.bt-text p {margin: 0}\n</style>\n</head>\n<body>\n<div class=\"wrapper\">\n<header>\n<h2 class=\"title\">\nStock Track | Veracyte Soars 7.81% Intraday Following Analyst Price Target Hike and Pipeline Updates\n</h2>\n\n<h4 class=\"meta\">\n\n\n<a class=\"head\" href=\"https://laohu8.com/wemedia/1086803395\">\n\n\n<div class=\"h-thumb\" style=\"background-image:url(https://static.tigerbbs.com/a81accab1e7ee4144dc051f71903a390);background-size:cover;\"></div>\n\n<div class=\"h-content\">\n<p class=\"h-name\">Stock Track </p>\n<p class=\"h-time\">2026-02-26 23:12</p>\n</div>\n\n</a>\n\n\n</h4>\n\n</header>\n<article>\n<p>Veracyte's stock soared 7.81% during intraday trading on Thursday, marking a significant upward movement for the diagnostics company.</p><p>The surge follows a bullish analyst update from Needham, where analyst Michael Matson maintained a Buy rating on the company and raised his price target to $48.00 from $44.00. The analyst cited accelerating growth, expanding margins, and pipeline-driven upside as key factors supporting the increased valuation.</p><p>Further positive sentiment is likely driven by the company's upcoming commercial and clinical activities. Veracyte plans to present numerous abstracts from its urology portfolio at a major medical symposium and is preparing to launch its TrueMRD test for muscle invasive bladder cancer, highlighting progress in its product pipeline.</p>\n\n</article>\n</div>\n</body>\n</html>\n","isBrief":false,"type":0,"news_type":1,"symbol":"VCYT","symbol_name":"Veracyte Inc","start_time":0,"source_url":"","article_id":"1120454129","we_media_id":"1086803395","thumbnails":[],"rights":null,"url":"https://stock-news.laohu8.com/highlight/detail?id=1120454129","pubTimestamp":1772118749,"columns":[],"sourceInfo":{"source_id":"ai_movement_en","name":"Stock Track"},"weMediaInfo":{"media_name":"Stock Track","introduction":"Track stock‘s movements and relevant news","home_visible":1,"id":"1086803395","head_image":"https://static.tigerbbs.com/a81accab1e7ee4144dc051f71903a390"},"summary":"Veracyte's stock soared 7.81% during intraday trading on Thursday, marking a significant upward movement for the diagnostics company.The surge follows a bullish analyst update from Needham, where...","collect":0,"end_time":0,"defaultTopTitle":"","property":[],"viewcount":null,"language":"en","relate_stocks":{"VCYT":"Veracyte Inc"},"translate_title":"股票追踪|分析师目标价上调和管道更新后，Veracyte盘中飙升7.81%","themeId":"","isJumpTheme":false,"ttsUrl":null,"symbols_score_info":{"VCYT":1},"content_text":"Veracyte's stock soared 7.81% during intraday trading on Thursday, marking a significant upward movement for the diagnostics company.The surge follows a bullish analyst update from Needham, where analyst Michael Matson maintained a Buy rating on the company and raised his price target to $48.00 from $44.00. The analyst cited accelerating growth, expanding margins, and pipeline-driven upside as key factors supporting the increased valuation.Further positive sentiment is likely driven by the company's upcoming commercial and clinical activities. Veracyte plans to present numerous abstracts from its urology portfolio at a major medical symposium and is preparing to launch its TrueMRD test for muscle invasive bladder cancer, highlighting progress in its product pipeline.","kind":"news","is_publish_news":true,"is_publish_highlight":false,"is_publish_live":false,"is_publish_wemedia":null,"editions":null,"column":"","sentiment":"1","news_tag":"movement","news_rank":0,"symbols":[],"gpt_button":1,"need_auth":false,"code":"91000000","status":"200"},"commentList":[],"isCommentEnd":true,"newsSizeData":{"likeSize":0,"commentSize":0,"repostSize":0,"favoriteSize":0,"likeStatus":false,"favoriteStatus":false},"APP":{"userAgent":"Mozilla/5.0 AppleWebKit/537.36 (KHTML, like Gecko; compatible; ClaudeBot/1.0; +claudebot@anthropic.com)","isDev":false,"isTTM":true,"tenantId":"TBGLOBAL","deviceId":"web-server-community-laohu8-v3","version":"4.36.2","shortVersion":"4.36.2","platform":"web","vendor":"web","appName":"ttm","isIOS":false,"isAndroid":false,"isTiger":false,"isTHS":false,"isWeiXin":false,"isWeiXinMini":false,"isWeiBo":false,"isQQ":false,"isBaiduSwan":false,"isBaiduBox":false,"isDingTalk":false,"isToutiao":false,"isOnePlus":false,"isHuaWei":false,"isXiaomi":false,"isXiaomiWebView":false,"isOppo":false,"isVivo":false,"isSamsung":false,"isMobile":false},"href":"/m/news/1120454129","isCrawlerRequest":true}